In de British Medical Journal verscheen recent onderstaand onderzoek naar de risico's op het ontwikkelen van kanker bij patienten met een metaal op metaal heupprothese. In de media is de laatste tijd veel ophef over de hogere concentraties van metaaldeeltjes in het bloed van deze patienten. Er wordt veel gesuggereerd over de rol die deze metaaldeeltjes hebben in de ontwikkeling van kanker, maar tot op heden zijn daarvoor nog weinig tot geen bewijzen geleverd in de literatuur.
Ook dit onderzoek geeft geen uitsluitsel, maar sluit uiteraard af met de woorden dat een langere observatie nodig is om tot de conclusie te komen dat de metaaldeeltjes niet gevaarlijk zijn voor de patient.
Metal-on-metal hip replacement patients at no more risk of developing cancer in seven years following surgery.
Longer term studies are required to assess risks after longer periods.
Research: The risk of cancer in the first seven years after metal-on-metal hip replacement compared with other bearings and the general population: a linkage study between the National Joint Registry of England and Wales and Hospital Episode Statistics.
Patients who have had metal-on-metal hip replacements are no more likely to develop cancer in the first seven years after surgery than the general population, although a longer-term study is required, a study published on bmj.com today claims.
A recent BMJ and BBC Newsnight investigation looked into the potentially high level of toxic metals from failing hip implants which may, in future, affect thousands of people around the world. The investigation also looked at why these hip replacements were allowed despite the risks being known and documented for decades. The BMJ has a large collection of articles about the safety of medical devices which can be found here: http://www.bmj.com/article-clusters.
This study, commissioned by the National Joint Registry of England and Wales and carried out by authors from the Universities of Bristol and Exeter, looks at whether these concerns are valid. The registry contains records of over one million procedures from at least 97% of orthopaedic units. Every year registry data and hospital episode statistics are linked up to check how patients who have had joint replacements are faring.
In this study cancer rates in patients with metal-on-metal hip replacements were compared with both a group of patients who had other hip bearing surfaces implanted and the general population. Overall, 14% (40 576) of registered patients had some type of metal-on-metal bearing surface: 7% (21 264) had a stemmed metal-on-metal prosthesis and 7% (19 312) had a resurfacing procedure. The researchers compared patients' outcomes using mathematical modelling. The models included the age and sex of the patient as well as three measures of general health at the time of hip surgery (the American Society of Anaesthesiologists grade that scores the patient's other serious illnesses, the number of distinct diagnostic codes recorded at time of surgery, and the number of NHS funded admissions to hospital in the previous five years). The authors do say, however, that comparison with the general population is not straightforward as hip replacement patients “tend to be healthier than others of the same gender and age group”.
Results show that the chance of a 60 year old man with moderate health and a metal-on-metal stemmed hip replacement being diagnosed with cancer in the five years following surgery is 6.2%, compared to 6.7% chance with hip replacement using other bearing surfaces. For women, these figures were 4.0% for metal-on-metal stemmed hip replacement and 4.4% for other bearing surfaces. Further results show that the incidence of cancer diagnosis is low after hip replacement and lower than that predicted for the age and sex matched general population.
The authors hope that this study will help clinicians reassure patients that the “risk of cancer for hip replacement patients is relatively low” with no evidence of an increase in cancer associated with metal-on-metal hips. They add though that this only shows results for up to seven years following surgery and the analysis of long-term data is required over the next few decades as some cancers take many years to develop.
Geen opmerkingen:
Een reactie posten